+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P13333(IL32 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

IL32 (Interleukin-32) is a proinflammatory cytokine first identified in 2005. encoded by the IL32 gene on human chromosome 16. Unlike classical interleukins, IL32 lacks a signal peptide but exerts diverse immunomodulatory roles by inducing other cytokines (e.g., TNF-α, IL-6. IL-1β) via NF-κB and p38 MAPK pathways. It exists in six splice variants (IL-32α to IL-32ζ), with IL-32γ being the most biologically active form. IL32 is expressed in immune cells (T cells, NK cells), epithelial tissues, and inflamed sites, and is implicated in autoimmune diseases, infections, and cancer.

IL32 antibodies are critical tools for detecting IL32 isoforms and studying their functional roles. They enable quantification of IL32 in clinical samples (e.g., serum, tissues) and facilitate mechanistic studies via neutralization or immunohistochemistry. Commercial IL32 antibodies are typically developed in rabbits or mice, targeting specific epitopes (e.g., N-terminal regions for isoform differentiation). Validation includes Western blot, ELISA, and flow cytometry. Challenges include cross-reactivity between isoforms and variability due to post-translational modifications. Recent research highlights IL32's dual role in cancer—promoting tumor growth in some contexts (e.g., lung cancer) while enhancing antitumor immunity in others—making IL32 antibodies valuable for both diagnostic and therapeutic exploration.